IDH2 and glioma: In clinical studies it is difficult to specifically correlate the better prognosis and prolonged overall survival of patients with IDH-mutant gliomas to the cellular behavior itself or the improved response to therapy treatment, since patients with gliomas receive standard therapy according to guidelines on management of gliomas in any case.